About - Taj Pharma (Oncology)
Taj Oncology is leading manufacturer of generic oncology products and biosimilars. Through its broad portfolio of products in Taj Pharma basket, oncology subsidiary is most innovative integrated portfolio with focus on affordability of quality products to treat cancer and help patients to see a ray of hope, we constantly strive to make high quality oncology products that offer treatment to cancer patients and improve the overall quality of life by reducing healthcare costs.
As largest generic pharmaceuticals manufacturers, Taj Oncology touches the lives of millions of patients every day. With one of the largest oncology portfolios in the industry, Taj has an unmatched impact on healthcare worldwide due to its affordable generics manufacturing. We are constantly involved in development of new products in the oncology sector, to create an alternative to high priced international brands.
Patients worldwide rely on Taj Oncology’s products to meet their medical needs. Ensuring an unrestricted supply of safe medicines is of critical importance to us, and doing so requires a secure, accountable supply chain of trusted partner companies worldwide, in order for development, registration and supply of oncology products.
About Taj Pharma Oncology
Our Vision
Taj Oncology is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, we set trends in research-intensive areas. Our products and services are designed to benefit people and improve their quality of life. At the same time we aim to create value through innovation, growth and high earning power.
Read MoreOur Promise
At Taj Oncology, we believe that a full range of products, from high-end oncology drugs to non-prescription drugs should be fully accessible and affordable to every patient and we consistently work on providing the best pharmaceutical solutions to the healthcare market.
Read MoreGold Standard™
"A generic oncology drug treatment is now available within many of the major cancer typology and this is often the 'gold standard' option for this condition. Opportunities exist to recommend schedules that encourage initiation of treatment with these 'gold standard' generic medicines.
Read MoreBio-Similar's
The World Health Organization:
A biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product.
The European Medicines Agency:
A biological medicine that is developed to be similar to an existing biological medicine (the ‘reference medicine’). When approved, a biosimilar’s variability and any differences between it and its reference medicine will have been shown not to affect safety or effectiveness
Generic Concept
Taj Pharma is one of the largest generic pharmaceutical company in India. We hold top positions in different established markets worldwide and are building a strong presence in many emerging generics markets.
Today, we market more than 500 branded and 4600 generics compositions to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
Read MoreTaj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.
